Libmeldy (Atidarsagene Autotemcel)

atidarsagene autotemcel, the active ingredient in Libmeldy, is a gene therapy presented as an autologous hematopoietic stem cell suspension for intravenous infusion. It is indicated for the treatment of metachromatic leukodystrophy in patients with late‑infantile or early‑juvenile disease onset.

GNH USA supplies Libmeldy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to maintain product integrity during global shipment. Customer support includes regulatory assistance and post‑delivery monitoring.

Libmeldy is a gene‑therapy product used to treat a lysosomal storage disorder. - Late‑infantile Metachromatic leukodystrophy: slows disease progression and improves neurological function. - Early‑juvenile Metachromatic leukodystrophy: reduces sulfatide accumulation and supports motor development. - Metachromatic leukodystrophy (any onset): provides sustained arylsulfatase A enzyme activity to modify disease course.

Libmeldy may cause a range of adverse reactions following infusion.

Common Side Effects: - Fever or chills - Nausea or vomiting - Headache - Fatigue or malaise - Infusion‑related reactions (e.g., erythema, itching) - Transient cytopenias

Serious or Rare Side Effects: - Graft failure or poor engraftment - Insertional oncogenesis leading to malignancy - Severe infections due to immunosuppression - Immune‑mediated reactions (e.g., cytokine release syndrome) - Organ toxicity (hepatic or renal impairment) - Neurological complications (seizures, encephalopathy)

Prior to administration, several safety considerations are required. - Patient selection: confirm diagnosis of metachromatic leukodystrophy and appropriate disease stage. - Pre‑infusion conditioning: a myeloablative regimen is typically required to enable engraftment. - Monitoring: conduct regular neurological assessments and laboratory tests for hematologic and organ function. - Risk of insertional mutagenesis: discuss potential long‑term oncogenic risk with patient or caregiver. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Libmeldy may interact with other therapies used in transplant or supportive care.

Major Interactions (Avoid): - Concurrent myeloablative chemotherapy agents that could impair stem‑cell engraftment. - Live vaccines administered within 6 months post‑infusion. - Other investigational gene‑therapy products targeting the same hematopoietic compartment.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., calcineurin inhibitors) that may affect immune reconstitution. - Antimicrobial prophylaxis agents (antibiotics, antifungals) requiring dose adjustments. - Anticoagulants used during apheresis procedures. - Supportive care medications such as anti‑emetics or analgesics.